The authors went on to test whether the level of HtrA1 expression could predict the response to chemotherapy of patients with ovarian or gastric cancer receiving cisplatin-based chemotherapy. The authors found that patients with ovarian or gastric tumors expressing higher levels of HtrA1 showed a better response to chemotherapy compared to those with lower levels of HtrA1 expression. The study reveals a novel pathway by which HtrA1 mediates the ability of chemotherapeutic agents to kill cancer cells, and suggests that loss of HtrA1 in ovarian and gastric cancer may contribute to the development of resistance to chemotherapy.
TITLE: Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity
AUTHOR CONTACT:
Elizabeth Zimmermann
Communications, Mayo Clinic Cancer Center, Rochester, Minnesota, USA.
Phone: (507) 284-5005; E-mail: newsbureau@mayo.edu .
View the PDF of this article at: https://www.the-jci.org/article.php?id=27698
Journal of Clinical Investigation